Ruxience and Dermatomyositis - a phase IV clinical study of FDA data

Summary:

Dermatomyositis is reported as a side effect among people who take Ruxience (rituximab-pvvr), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Prednisone, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Dermatomyositis when taking Ruxience. It is created by eHealthMe based on reports of 4,258 people who have side effects when taking Ruxience from the FDA, and is updated regularly.

What is Ruxience?

Ruxience has active ingredients of rituximab-pvvr. eHealthMe is studying from 4,260 Ruxience users. Check the latest studies of Ruxience.

What is Dermatomyositis?

Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer) is found to be associated with 263 drugs and 416 conditions by eHealthMe. Check the latest studies of Dermatomyositis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

4,258 people reported to have side effects when taking Ruxience.
Among them, 20 people (0.47%) have Dermatomyositis.

Among these 20 people:

How long have people been on Ruxience when they have Dermatomyositis? *

What is the gender of people who have Dermatomyositis when taking Ruxience? *

female: 84.21 %
male: 15.79 %

What is the age of people who have Dermatomyositis when taking Ruxience? *

What are other drugs people take besides Ruxience? *

Prednisone: 9 people, 45.00%
Acetaminophen: 8 people, 40.00%
Sulfatrim: 8 people, 40.00%
Methylprednisolone: 7 people, 35.00%
Benadryl: 4 people, 20.00%
Calcium: 4 people, 20.00%
Coumadin: 4 people, 20.00%
Diphenhydramine Hydrochloride: 4 people, 20.00%
Folic Acid: 4 people, 20.00%
Lansoprazole: 4 people, 20.00%

What are other side effects people have besides Dermatomyositis? *

Weakness: 8 people, 40.00%
Drug Ineffective: 8 people, 40.00%
High Blood Pressure: 7 people, 35.00%
Headache (pain in head): 7 people, 35.00%
Joint Pain: 7 people, 35.00%
Blood Pressure Fluctuation: 5 people, 25.00%
Nausea (feeling of having an urge to vomit): 5 people, 25.00%
Blood Pressure Systolic Abnormal: 4 people, 20.00%
Blood Pressure Diastolic Abnormal: 4 people, 20.00%
Iron Deficiency: 4 people, 20.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 45.00%
Antisynthetase Syndrome (chronic autoimmune disease of unknown cause): 7 people, 35.00%
Myositis (inflammation of the muscles): 4 people, 20.00%
Interstitial Lung Disease: 4 people, 20.00%
Periorbital Oedema (swelling around the eyes): 3 people, 15.00%
Folliculitis (infection of hair root): 3 people, 15.00%
Microscopic Polyangiitis (inflammation involving multiple blood or lymph small-vessel): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ruxience and have Dermatomyositis?

- Check whether Dermatomyositis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ruxience:

Ruxience (4,260 reports)

Dermatomyositis treatments and more:

Dermatomyositis (8,399 reports)

Browse all side effects of Ruxience:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatomyositis:

Dermatomyositis (263 drugs)

Browse all the conditions that are associated with Dermatomyositis:

Dermatomyositis (416 conditions)

Related publications that referenced our studies

Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on rituximab-pvvr (the active ingredients of Ruxience) and Ruxience (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.